Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > News > American Pharmaceutical Partners Reports Tolerability of High Dose

June 8th, 2004

American Pharmaceutical Partners Reports Tolerability of High Dose

Abstract:
Abraxis Oncology, a division of American Pharmaceutical Partners, Inc. today reported results of a Phase I dose-escalation study of ABRAXANETM (albumin nanoparticle paclitaxel) that indicated this investigational drug is well-tolerated at high doses in a weekly dosing schedule for non-hematologic malignancies such as lung, ovarian and metastatic breast cancer and patients who have had prior chemotherapies.

Source:
APP

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

New chip makes testing for antibiotic-resistant bacteria faster, easier: Researchers at the University of Toronto design diagnostic chip to reduce testing time from days to one hour, allowing doctors to pick the right antibiotic the first time May 28th, 2015

Arrowhead to Present at Jefferies 2015 Healthcare Conference May 27th, 2015

Seeing the action: UCSB researchers develop a novel device to image the minute forces and actions involved in cell membrane hemifusion May 27th, 2015

Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project